Lilly to acquire POINT Biopharma for $12.50/share, or $1.4bn $LLY $PNT investor.lilly.com/news-releases/…

Centerview Partners acted as Exclusive Financial Advisor to POINT Biopharma on its sale to Lilly

Ajinomoto Co. to Acquire Forge Biologics for $620 Million forgebiologics.com/ajinomoto-co-i…

Centerview Partners acted as Financial Advisor to Forge Biologics on its sale to Ajinomoto Co.

Roche to acquire Carmot Therapeutics for up to $3.1bn; or $2.7bn upfront plus $400M in Milestones carmot.us/carmot-therape…

Centerview Partners acted as financial advisor to Carmot Therapeutics

AbbVie to acquire Cerevel Therapeutics for $45/sh, or $8.7bn investors.cerevel.com/news-releases/…

Centerview Partners acted as financial advisor to Cerevel Therapeutics on its sale to Abbvie

AstraZeneca to acquire Icosavax for $15+$5; or up to $1.1bn $ICVX $AZN investors.icosavax.com/news-releases/…

Centerview Partners acted as Exclusive Financial Advisor to Icosavax on its sale to AstraZeneca

$GRCL Gracell Biotechnologies to be acquired by AstraZeneca for $10+$1.50CVR, or up to $1.2bn $AZN ir.gracellbio.com/news-releases/…

Centerview Partners acted as Exclusive Financial Advisor to Gracell on its sale to AstraZeneca

$RYZB RayzeBio to be acquired by Bristol Myers Squibb for $62.50/sh, or $4.1bn $BMS news.bms.com/news/details/2…

Centerview Partners acted as Exclusive Financial Advisor to RayzeBio on its sale to Bristol Myers Squibb

$HARP Harpoon Therapeutics to be acquired by Merck $MRK for $23/sh, or $680M businesswire.com/news/home/2024…

Centerview Partners acted as Exclusive Financial Advisor to Harpoon on its sale to Merck

Ambrx to be acquired by Johnson & Johnson for $28/sh, or $2bn businesswire.com/news/home/2024…

Centerview Partners acted as Financial Advisor to Ambrx on its sale to Johnson & Johnson

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B Inhibrx, Inc. shareholders will receive $30/sh in cash, a $5 CVR, 0.25 shares in New Inhibrx, a new publicly traded company that retains all non-101 assets of Inhibrx prnewswire.com/news-releases/…

Centerview Partners acted as Exclusive Financial Advisor to Inhibrx $INBX $SNY